Propafenone
- Generic Name
- Propafenone
- Brand Names
- Rythmol
- Drug Type
- Small Molecule
- Chemical Formula
- C21H27NO3
- CAS Number
- 54063-53-5
- Unique Ingredient Identifier
- 68IQX3T69U
- Background
An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated.
- Indication
Used to prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. Also used for the treatment of life-threatening documented ventricular arrhythmias, such as sustained ventricular tachycardia.
- Associated Conditions
- Atrial Fibrillation, Paroxysmal Atrial Fibrillation (PAF), Paroxysmal Supraventricular Tachycardia (PSVT), Ventricular Arrhythmia
- Associated Therapies
- -
Efficacy and Safety of Electrical Versus Pharmacological Cardioversion in Early Atrial Fibrillation
- Conditions
- Interventions
- First Posted Date
- 2009-07-07
- Last Posted Date
- 2009-07-07
- Lead Sponsor
- Valduce Hospital
- Target Recruit Count
- 247
- Registration Number
- NCT00933634
- Locations
- 🇮🇹
Emergency Unit - Valduce Hospital, Como, Italy
High Intensity Focused Ultrasound (HIFU) Ablation System Study
- Conditions
- Interventions
- First Posted Date
- 2006-10-25
- Last Posted Date
- 2008-06-17
- Lead Sponsor
- ProRhythm, Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT00392106
- Locations
- 🇺🇸
Piedmont Hospital, Atlanta, Georgia, United States
🇺🇸Lahey Clinic, Burlington, Massachusetts, United States
🇺🇸Stony Brook University Hospital, Stony Brook, New York, United States
Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)
- Conditions
Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE)
- Conditions
- First Posted Date
- 1999-10-28
- Last Posted Date
- 2013-07-29
- Lead Sponsor
- University of Washington
- Registration Number
- NCT00000464
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.